Share This Article:

Exenatide efficacy in unselected patients: Comparison with clinical trials

Abstract Full-Text HTML Download Download as PDF (Size:182KB) PP. 118-121
DOI: 10.4236/jdm.2012.21019    3,844 Downloads   6,262 Views   Citations


Exenatide is a Glucagon-Like Peptide-1 (GLP-1) analog improving fasting and post-prandial glycaemia, approved in patients treated with a combination of sulfonylureas and metformin and not achieving good metabolic control. This retrospective cohort study compared the efficacy and safety of exenatide in unselected patients with outcomes of FDA trials and other uncontrolled published studies. Exenatide was prescribed in 108 patients between April 2008 and December 2009, 80% of the patients were treated with 10 ug of exenatide twice daily. Mean follow up was 4.5 months for the 1st follow up. Changes in HbA1c (-1.1%), BMI (-1.1) and fasting glucose (-0.61 g/l) from baseline were significant, and coherent with controlled trials. 32% of patients had at least one side effect, often gastro intestinal. 23% stopped the treatment, a quarter (1/4) of which for inefficacity. Patients with a higher BMI (>40) (n = 29) at baseline did not show a better response in HbA1c or weight. Results at the second follow-up show a slight tendency of rising on HbA1c, BMI and fasting blood glucose. Finally, a third follow-up at a mean of 17 months is available for 11 patients, which shows stability in HA1c, BMI and fasting glucose. In our experience, Exenatide was safe and effective in reducing HbA1c and weight in patients who were able to tolerate it. Our results are close to results published elsewhere. There are still gaps in the literature on exenatide, especially on the long term effect, which need to be assessed by more publications.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Collet-Gaudillat, C. , Petit-Aubert, G. , Desforges-Bullet, V. and Beressi, J. (2012) Exenatide efficacy in unselected patients: Comparison with clinical trials. Journal of Diabetes Mellitus, 2, 118-121. doi: 10.4236/jdm.2012.21019.


[1] Turner, R.C., Cull, C.A., Frighi, V. and Holman, R.R. (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association (JAMA), 281, 2005-2012. doi:10.1001/jama.281.21.2005
[2] Iltz, J.L., Baker, D.E., Setter, S.M. and Keith Campbell, R. (2006) Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics, 28, 652-665. doi:10.1016/j.clinthera.2006.05.006
[3] Buse, J.B., Henry, R.R., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2004) Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 27, 2628-2635. doi:10.2337/diacare.27.11.2628
[4] DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100. doi:10.2337/diacare.28.5.1092
[5] Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. and Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083-1091. doi:10.2337/diacare.28.5.1083
[6] Norris, S.L., Lee, N., Thakurta, S. and Chan, B.K. (2009) Exenatide efficacy and safety: A systematic review. Diabetic Medicine, 26, 837-846. doi:10.1111/j.1464-5491.2009.02790.x
[7] Donekal S. and Shomali ME. (2008) Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials. Diabetes Research and Clinical Practice, 80, e4-e6. doi:10.1016/j.diabres.2008.01.014
[8] Brixner, D.I., McAdam-Marx, C., Ye, X., Boye, K.S., Nielsen, L.L., Wintle, M., Misurski, D. and Fabunmi, R. (2009) Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism, 11, 1122-1130. doi:10.1111/j.1463-1326.2009.01081.x
[9] Buse, J.B., Klonoff, D.C., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., Maggs, D.G. and Wintle, M.E. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics, 29, 139-153. doi:10.1016/j.clinthera.2007.01.015

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.